We have recently observed that treatment with the small molecule DMA inhibits the secretion of sEVs by MDA231 cells, impairing the autocrine activation of TGF‐β signalling in these breast cancer cells in vitro and in vivo (Teixeira et al. Here, TGFB1 is linked to breast carcinoma.